Erschienen in:
30.10.2018 | Original Article
An overview of the ATOMS generations: port types, functionality and risk factors
verfasst von:
Sandra Mühlstädt, Alexander Friedl, Roman Zachoval, Nasreldin Mohammed, André Schumann, Gerit Theil, Paolo Fornara
Erschienen in:
World Journal of Urology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Abstract
Background
We report the multicentre comparison of the different port types of the adjustable transobturator male incontinence system (ATOMS, A.M.I., Austria).
Methods
Between 10/09 and 10/16, 383 patients received an ATOMS. Of these, 63% received the inguinal port (IP, 2009–2013), 23% the intraoperative manually connectable scrotal port (SP, 2013–2015), and 14% the pre-connected fully silicone-covered scrotal port (SSP, 2014–2016). During the follow-up period, continence parameters, pain and quality of life ratings and postoperative port-associated complications were evaluated and compared. Statistical analysis was performed with GraphPad Prism 7®, p < 0.05 considered as significant.
Results
Regarding preoperative parameters (BMI, ASA score, previous radiotherapy/incontinence surgery, and preoperative 24-h pad count/24-h pad test), no significant differences were found. Regarding perioperative parameters, the mean operative time was significantly shorter for the SP and SSP (IP vs. SP p < 0.0001, IP vs. SSP p = 0.0048, SP vs. SSP p = 0.697). Comparison of the postoperative 24-h pad count, 24-h pad test and uroflowmetry data revealed no significant differences. However, the postoperative ICIQ-SF score was significantly better for the SSP (p = 0.0232) than the SP. A significant difference was also observed in postoperative port-associated complications. According to the Clavien–Dindo classification, we identified one grade I and 29 grade IIIb complications for the IP, 1 grade I and 6 grade IIIb complications for the SP, but only 2 grade IIIb complications for the SSP (IP vs. SP p = 0.0231, IP vs. SSP p = 0.0189 and SP vs. SSP p = 0.0453).
Conclusion
The SSP shows fewer complications while retaining comparable efficacy.